At a glance
ClinicalIndex Comparison RecordN/ACompleted· 112 enrolled
Drug / intervention
Angiotensin converting enzyme inhibitor +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effects of RAS Inhibitors (ARB, ACEi, DRI) in People With Hypertension 1-2 Stages on the Course of COVID-19 (BIRCOV Trial: ARB, ACEI, DRi Effects on COVID-19)
In Brief
An observational study evaluating Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, and 1 other intervention for Hypertension and COVID-19. Completed, enrolled 112 participants across 1 site.
Detailed Summary
It is supposed to monitor hypertensive patients who are infected or have clinical manifestations of COVID-19 for 1 month after the onset of the disease. Three groups will be considered: 1. receiving ACE inhibitors 2. receiving ARBs 3. receiving DIR.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension, COVID-19
CountriesUkraine
Collaborators--
Timeline
N/ACompletedFinished
202120222023202420252026
Enrollment StartApr 2020
First PostedApr 2020
Primary CompletionJul 2021
Study CompletionAug 2021
TodayJul 2026
First PostedApr 28, 2020
Enrollment StartApr 1, 2020
Primary CompletionJul 24, 2021
Study CompletionAug 1, 2021
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 6.2 years ago
Interventions
Angiotensin converting enzyme inhibitordrug
routine drug intake
Angiotensin Receptor Blockersdrug
routine drug intake
Direct renin inhibitordrug
routine drug intake